OTCMKTS:BRRGF BerGenBio ASA (BRRGF) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free BRRGF Stock Alerts $0.03 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.03▼$0.0350-Day Range$0.03▼$0.0352-Week Range$0.03▼$0.03VolumeN/AAverage Volume200 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get BerGenBio ASA alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About BerGenBio ASA Stock (OTCMKTS:BRRGF)BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of novel medicines to treat immune-evasive, drug resistant, and metastatic cancers; and respiratory diseases. It develops bemcentinib, an oral once-a-day inhibitor of AXL receptor tyrosine kinase, which is in Phase 1b/2a clinical trial to treat non-small cell lung cancer, and Phase 2 clinical trial to treat acute myeloid leukemia and COVID-19. Bemcentinib is also being studied for glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma. In addition, the company is developing tilvestamab, an anti-AXL function-blocking monoclonal antibody that is in Phase 1b clinical trial for the treatment of ovarian cancer; and mipasetamab uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. It has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.Read More BRRGF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRRGF Stock News HeadlinesMarch 20, 2024 | finance.yahoo.comBerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutationFebruary 7, 2024 | finance.yahoo.comBerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory InfectionsApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.January 31, 2024 | lse.co.ukGram Car Carriers Asa Share Price (GCC.OL)December 2, 2023 | sg.finance.yahoo.comBerGenBio ASA (BRRGF) stock historical prices & data – Yahoo FinanceNovember 18, 2023 | morningstar.comBerGenBio ASA BGBIONovember 14, 2023 | finance.yahoo.comBerGenBio Reports Third Quarter 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comBerGenBio Announces Data from Biomarker Analyses in 2L NSCLCApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.October 31, 2023 | finance.yahoo.comBerGenBio Announces Poster Presentation at Upcoming SITC MeetingOctober 23, 2023 | finance.yahoo.comNew Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO MeetingOctober 16, 2023 | finance.yahoo.comAdditional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meetingAugust 23, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on BerGenBio AS (BRRGF)August 22, 2023 | finance.yahoo.comBerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung CancerAugust 15, 2023 | bbc.co.ukCoronation concert ballot misleading, says regulator ASAMay 26, 2023 | finance.yahoo.comBerGenBio ASA: Approval and publication of prospectus for the preferential Rights IssueMay 16, 2023 | markets.businessinsider.comBerGenBio AS (BRRGF) Gets a Buy from H.C. WainwrightApril 25, 2023 | finance.yahoo.comBerGenBio ASA: Proposed partially underwritten rights issueMarch 9, 2023 | finance.yahoo.comBerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 MutationsFebruary 17, 2023 | finanznachrichten.deBerGenBio ASA: BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsFebruary 16, 2023 | finance.yahoo.comBerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateFebruary 15, 2023 | finance.yahoo.comBerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsNovember 15, 2022 | finance.yahoo.comBerGenBio reports third quarter 2022 financial results and provides business updateOctober 25, 2022 | prnewswire.comBerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva ASOctober 11, 2022 | finance.yahoo.comBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 MutationsSeptember 27, 2022 | finance.yahoo.comBERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTSSeptember 10, 2022 | reuters.comBGBIO.OL - Bergenbio ASA | Stock Price & Latest News | ReutersSee More Headlines Receive BRRGF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BerGenBio ASA and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:BRRGF CUSIPN/A CIKN/A Webwww.bergenbio.com Phone47 53 50 15 64FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Martin Olin (Age 55)Chief Executive Officer Comp: $880.14kMr. Rune Skeie (Age 51)Chief Financial Officer Comp: $237.76kMs. Gayle M. Mills M.B.A (Age 69)Chief Business Officer Ms. Cristina Oliva M.D.Chief Medical OfficerGraham MorellHead of IRDr. Akil JacksonMedical DirectorMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors BRRGF Stock Analysis - Frequently Asked Questions Should I buy or sell BerGenBio ASA stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BerGenBio ASA in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" BRRGF shares. View BRRGF analyst ratings or view top-rated stocks. How have BRRGF shares performed in 2024? BerGenBio ASA's stock was trading at $0.0250 at the beginning of the year. Since then, BRRGF shares have increased by 0.0% and is now trading at $0.0250. View the best growth stocks for 2024 here. How do I buy shares of BerGenBio ASA? Shares of BRRGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BRRGF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BerGenBio ASA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
